Drug intelligence / Profile preview

BAY 987519 (Bayer)

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Topical

Overview

BAY 987519 is an experimental topical sunscreen formulation developed by Bayer's Consumer Care division. It was primarily investigated for its photoprotective properties, specifically its ability to provide broad-spectrum protection against ultraviolet A (UVA) and ultraviolet B (UVB) radiation. Clinical evaluation of BAY 987519 focused on determining its Sun Protection Factor (SPF) and UVA Protection Factor (UVAPF) in healthy volunteers. The formulation functions by utilizing UV-filtering agents that absorb, reflect, or scatter solar radiation on the skin's surface, thereby preventing the inflammatory response known as erythema (sunburn) and reducing the risk of long-term actinic damage and skin cancer.

Beyond the preview

Go deeper on BAY 987519 (Bayer).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY 987519 (Bayer).

Explore the full profile